Structure of the Toll/Interleukin-1 Receptor (TIR) Domain of the B-cell Adaptor That Links Phosphoinositide Metabolism with the Negative Regulation of the Toll-like Receptor (TLR) Signalosome by Halabi, Samer et al.
Structure of the Toll/Interleukin-1 Receptor (TIR) Domain of
the B-cell Adaptor That Links Phosphoinositide Metabolism
with the Negative Regulation of the Toll-like Receptor (TLR)
Signalosome*□S
Received for publication,October 2, 2016, and in revised form, November 15, 2016 Published, JBC Papers in Press,December 1, 2016, DOI 10.1074/jbc.M116.761528
Samer Halabi1, Eiki Sekine, Brett Verstak, Nicholas J. Gay2, and Martin C. Moncrieffe3
From the Department of Biochemistry, Cambridge University, Cambridge CB2 1GA, United Kingdom
Edited by Alex Toker
Ligand binding to Toll-like receptors (TLRs) results in
dimerization of their cytosolic Toll/interleukin-1 receptor
(TIR) domains and recruitment of post-receptor signal trans-
ducers into a complex signalosome. TLR activation leads to the
production of transcription factors and pro-inflammatory mol-
ecules and the activation of phosphoinositide 3-kinases (PI3K)
in a process that requires the multimodular B-cell adaptor for
phosphoinositide 3-kinase (BCAP). BCAPhas a sequence previ-
ously proposed as a “cryptic” TIR domain. Here, we present the
structure of the N-terminal region of human BCAP and show
that it possesses a canonical TIR fold. Dimeric BCAP associates
with the TIR domains of TLR2/4 and MAL/TIRAP, suggesting
that it is recruited to the TLR signalosome by multitypic TIR-
TIR interactions. BCAP also interacts with the p85 subunit of
PI3KandphospholipaseC, enzymes that deplete plasmamem-
brane phosphatidylinositol 4,5-bisphosphate (PIP2), and these
interactions provide a molecular explanation for BCAP-medi-
ated down-regulation of inflammatory signaling.
Phosphoinositide 3-kinases (PI3Ks) are crucial mediators of
various cellular processes including growth, survival, prolifera-
tion, migration, metabolism, and membrane transport. Dys-
function in the PI3K signaling network is a major driver of
oncogenesis (1–4). The well characterized class Ia PI3Ks phos-
phorylate primarily at the D-3 position of the inositol ring, cre-
ating a site that enables the interaction of proteins with the
plasma membrane. Class Ia PI3Ks are heterodimers comprised
of regulatory (p85, p55, or p50) and catalytic (p110) subunits
(5). The regulatory subunit not only represses the activity of
the catalytic subunit in unactivated cells but mediates its
activation by interacting directly with phosphorylated tyro-
sine residues present on activated growth factor receptors or
adaptor molecules.
One such adaptor, B-cell adaptor for phosphoinositide 3-ki-
nase (BCAP),4 functions in linking the B-cell receptor (BCR)
and the co-receptor CD19 to the activation of PI3K via interac-
tion with the SH2 domains on the regulatory p85 subunit (6).
Architecturally, BCAP contains well defined ankyrin repeats
and a Dof/BANK/BCAP (DBB) domain; the latter was first
reported in theDrosophila protein Dof, where it is required for
FGF-dependent signaling (7, 8), and a homologous domain
exists in the B-cell scaffold with ankyrin repeat (BANK) protein
(9).
The expression and cellular distribution of BCAP suggest
that it is involved in immunological processes in addition to
regulation of BCR (10, 11). In mice, BCAP is specifically
expressed not only in B-cells but also inmacrophages, dendritic
cells, and lymphocyte natural killer cells (13). BCAP is mainly
localized in the cytosol and the plasmamembrane of expressing
cells, and there are two splice variants in chicken, humans, and
mice (6). Full-length BCAP is designated BCAPL, and the sec-
ond largest splice variant is designated BCAPS.
BCAPL is recruited into activated complexes of Toll-like
receptors (TLRs) and associated signaling adaptor proteins.
TLRs are pattern recognition receptors that respond to micro-
bial products such as lipopolysaccharide from Gram-negative
bacteria. The TLRs and the signaling adaptors MyD88 and
MAL/TIRAP contain TIR domains, and these interact via
homo- or heterotypic interactions to form complexes that con-
stitute the post-receptor signalosome. A recent study predicted
the existence of a TIR domain in the N-terminal region of
BCAPL that is required for negative regulation of inflammatory
signaling by TLRs (14). RNAi depletion of BCAPL frommacro-
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phages enhanced the LPS-induced production of NF-B and
the inflammatory cytokines IL-6 and IL-10 but not TNF- (10),
which suggests that it negatively regulates inflammation. Sim-
ilar results were obtained upon stimulation of TLR2/6, TLR3,
and TLR7 by their respective ligands (10). In contrast, RNAi-
mediated depletion of BCAPS, a splice variant that lacks the
putative TIR domain, is a positive regulator of inflammation
(10).
Crosstalk between the TLR and PI3K pathways could be
facilitated by the TIR domains on the TLR receptors or any of
the well characterized TLR adaptor proteins TIRAP, MyD88,
TRIF, TRAM, or SARM. However, the situation is more com-
plex. Tyrosine phosphorylation of the YXXM motif on BCAP,
the first of which lies outside of the putative TIR domain,
enables interaction with the SH2 domain of p85 (6, 12, 15).
Additionally, isolated B-cells from BCAP knockdown mice
exhibited decreased calcium mobilization, which was attrib-
uted to a decrease in the activation of the enzyme PLC2 (16).
PLC2, like p85, has both SH2 and SH3 domains, and its
decreased activationmay be the result of direct interactionwith
BCAP (16). The PLC2 signaling pathway has been implicated
in TLR4 signaling (17), but the molecular mechanisms and
interactions are poorly understood.
Here we present the structure of the N-terminal domain of
BCAP, firmly establishing it as aTIRdomain.We also show that
full-length BCAP is dimeric and that its oligomerization is de-
pendent on its ANK and DBB domains. Furthermore, we show
that BCAP TIR associates with the MAL/TIRAP adaptor and
the TIR domains of TLRs. BCAP also binds to PLC2, and this
interaction does not inhibit its association with the tyrosine
kinases Syk and Lyn. The interaction between BCAP and the
TLRs, as well as its interaction with PI3K and PLC2, suggests
that BCAP plays a central role in crosstalk between the TLR,
PI3K, and PLC2 pathways.
Results
Structure of the N-terminal TIR Domain of Human BCAP—
The N-terminal domain of BCAP comprising residues 7–142
was solubly expressed in Escherichia coli. The structure was
solved at 2.5Åusing data derived fromprotein crystals inwhich
the lysine residues were dimethylated and single-wavelength
anomalous dispersion phasing with 5-amino-2,4,6-triiodo-
isophthalic acid monohydrate (18). Data collection, phasing,
and refinement statistics are summarized in supplemental
Table 1. There was a single molecule in the asymmetric unit,
and the structure reveals that the N-terminal region adopts a
typical TIR domain fold (Fig. 1A). The TIR domain of BCAP is
composed of five parallel -strands (A–E) surrounded by
five -helices(A–E). The third -helix has a kink and forms
two helices, C and C, and the fourth is distorted. The loop
regions, with the exception of the biologically important BB-
loop, which connects the B-strand to the B-helix, were well
defined in the electron density, and unlike the structure of the
MAL-TIR domain (19), there are no disulfide bonds.
Using the PDBeFOLD (20) and VAST (21) servers, the clos-
est structural homologues were both TLR2-TIR domain
mutants (22, 23) (Protein Data Bank (PDB) codes 1FYX and
1O77, respectively), although the sequence identity between
the TLR2-TIR domain and BCAP-TIR is only 12%. Other close
homologues include theTIRdomain of the interleukin-1 recep-
tor, IL-1RAPL (24), as well asMAL/TIRAP (19, 25) and the TIR
domain of TLR10 (26). Secondary structural alignment of the
BCAP TIR domain to its closest structural homologues is
shown in Fig. 1, C and D. The BB-loop in BCAP is longer and
not as rigid as that in TLR2. BCAP is less compact than MAL/
TIRAP, which lacks the BB-loop and also contains two disulfide
bonds. Strikingly, the orientation of the B-sheet and the
B-helix of BCAP TIR domain is such that it extends out of the
FIGURE 1. Structure of the TIR domain of human BCAP. A and B, the BCAP TIR domain has the typical TIR fold consisting of five parallel -strands A–E)
surrounded by five helices (A–E). C and D, structural superposition of BCAP-TIR and the TIR domain of TLR2 (C) and MAL/TIRAP (D). Electrostatic surface
potential of BCAP-TIR (E and F) using the orientations shown in panels A and B is colored from 5 (red) to 5 kcal/mol (blue). Electrostatic potentials were
calculated using Chimera.
TIR Domain of the BCAP Adaptor
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domain core in comparison with that of MAL/TIRAP. With
regard to sequence conservation across the structurally homo-
logous TIR domains, there are five highly conserved residues
including Ser-17 (A-loop), Leu-32 (A), Pro-49 (B), Leu-
101, and Leu-102 (D) (supplemental Fig. 1). The electrostatic
potential of the solvent-accessible surface of BCAP (Fig. 1, E
and F) reveals distinct regions of negative and positive potential
in addition to hydrophobic patches, suggesting that the TIR
domain of BCAP may interact with diverse TIR domain-con-
taining proteins. For example, the TIR domain of MAL/TIRAP
is predominantly hydrophobic but has acidic and small basic
patches (19), which could, in principle, interact with acidic or
basic surfaces on BCAP-TIR. In contrast, the TIR domain of
MyD88 has significant regions of basic residues that may inter-
act with the acidic surface on the TIR domain of BCAP.
Given the necessity of TIR-TIR interactions to signal propa-
gation, severalmutationsweremade to explore possible regions
on BCAP that may be involved in its association with MAL/
TIRAP. Sequence alignments of BCAP and proteins known to
interact with MAL/TIRAP (MyD88, p85, A46, and TRAF6)
revealed three conserved residues (Leu-70, Asp-117, and Leu-
401). Two of these (Leu-70 and Asp-117) lie within the TIR
domain, and all were mutated to alanine. Additionally, the
highly conserved B loop proline residue (Pro-49), which
directs adaptor specificity inTLRs (27), wasmutated to aspartic
acid and alanine, respectively. The co-immunoprecipitation
data for these mutants and MAL/TIRAP (supplemental Fig. 3)
suggest that Pro-49 is not required for the interaction. Both the
D75A and L401A mutations exhibited reduced binding,
whereas theD117Amutation abolishes the interaction between
BCAP andMAL/TIRAP.Asp-117 is located in a region of acidic
surface potential sandwiched between the D-helix and
E-sheet, and it is likely that this region interacts with a basic
patch onMAL/TIRAP. The reduced association observed with
the L401Amutant suggests that the determinants of the BCAP-
MAL/TIRAP interaction may not solely reside within the TIR
domain, and it is likely that there are other regions involved in
the BCAP-MAL/TIRAP hetero-association.
Full-length BCAP Is Dimeric, but the TIR Domain Is
Monomeric—Analytical ultracentrifugation (AUC) experi-
ments were performed on purified samples of full-length
BCAPL and an N-terminal region spanning residues 7–142,
which contains the TIR domain. The sedimentation velocity
data, the residuals after fitting, and the c(S) distribution are
shown in Fig. 2. The sedimentation coefficient values were
4.70 1013 s and 1.82 1013 s for BCAPL and the N-termi-
nal domain, respectively. The qualities of the fitswere very good
with root mean square deviation values of 0.007 (BCAPL) and
0.005 (N-terminal domain). Additionally, the frictional coeffi-
cient was well determined, and this allows estimation ofmolec-
ular masses from the sedimentation velocity data. Using c(M)
analyses, the molecular masses are 165 and 18 kDa for BCAPL
and the TIR domain, respectively. These values are within
10% of those expected for dimeric BCAPL and monomeric
N-terminal domain on the basis of their amino acid sequence.
Weight-averaged molecular masses obtained from an analysis
of the SEC-MALS (supplemental Fig. 2, A and C) data are con-
sistent with those obtained by AUC.
The DBB and ANK Domains Mediate BCAP Oligomeri-
zation—Themonomeric nature of the TIR domain implies that
the determinants of BCAPL self-association lie outside this
region. To clearly define the regions responsible for BCAPL
oligomerization, the splice variant (BCAPS) and a truncated
molecule comprising the first 330 residues of BCAPL
(BCAP330), which contains the TIR and DBB domains, were
expressed, and their hydrodynamic behavior was studied by
sedimentation velocity. Fig. 3 shows an analysis of the sedimen-
tation velocity data for these constructs, and both, like BCAPL,
aredimeric. SEC-MALSdata forBCAP330 (supplemental Fig. 2B)
also confirm that it is dimeric. Because BCAP330 contains the
DBB domain, this confirms that it is, at least in part, responsible
for the self-association of BCAPL. The ankyrin repeats are also
known to facilitate oligomerization (28), and together with the
DBB domain, they may enhance self-association.
Human BCAP Interacts with MyD88, MAL/TIRAP, TLR2,
TLR4, and SARM but Not TRAM—TIR domains associate via
homotypic interactions, and the presence of anN-terminal TIR
FIGURE 2.AUC analysis of full-length BCAP and TIR domain. A and B, sedimentation velocity data, residuals, and the sedimentation coefficient distribution,
c(S), for full-length BCAP (A) and theN-terminal region comprising residues 7–142 (B). The recoveredmolecularmasses froma c(M) analysis are also shown. The
frictional coefficient was well determined, and as a result, the molecular masses are reliable. Full-length BCAP is dimeric, and the N-terminal domain is
monomeric. Every third scan is shown for clarity.
TIR Domain of the BCAP Adaptor
654 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 2•JANUARY 13, 2017
 at Cam
bridge U
niversity Library on February 23, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
domain in BCAP could potentially enable binding with the
cytosolic adaptor proteins involved in the TLR pathway. To
determine whether BCAPL interacts with TRAM, SARM, and
MyD88, pulldown assays were performed.HEK 293T cells were
transiently transfected with Myc-TRAM, FLAG-SARM, Myc-
MyD88, and Myc-MyD88-FXXM mutant in the presence of
either Myc-BCAP or FLAG-BCAP. BCAP showed no interac-
tion with Myc-TRAM (Fig. 4A) but interacted with FLAG-
SARM (Fig. 4B) and also with Myc-MyD88 and the Myc-
MyD88-FXXMmutant (Fig. 4C).
The nature of the interaction between BCAP and TIRAPwas
also probed by a yeast two-hybrid assay utilizing a construct
consisting of the first 434 amino acids of BCAP (BCAP-TDA).
This construct includes the dimerization site, two of the four
YXXM motifs present in the full-length protein, and the TIR,
DBB, and ANK domains. BCAP-TDA was tested against full-
length constructs of MAL/TIRAP and its mutants D96N and
S180L, the TIR domains of TLR2 and TLR4, and also the regu-
latory p85 subunit of PI3K. In these experiments, all proteins
tested interacted with BCAP-TDA (see supplemental Fig. 4).
Interestingly, the disease-associated MAL/TIRAP variants
S180L (29) and D96N (30) also bind BCAP-TDA, strongly sug-
gesting a different binding mode to that proposed for MyD88
(19).
BCAP Associates with PLC2, Lyn, and Syk—BCAPL is
involved in the BCR-mediated activation of PLC2 and PI3K
(6). The interaction between BCAPL and PI3K is direct and is
known to involve at least one of two SH2 domains on the reg-
ulatory p85 subunit of PI3K. The p85 subunit also has an SH3
domain that is separated from the first N-terminal SH2 domain
by a Rho-GAP domain (5, 31), and it is not known whether this
domain is involved in the interaction with BCAP. Like p85,
PLC2 contains two SH2 domains and an SH3 domain, and
given the similarities in domain structure, we hypothesized that
BCAP could interact with PLC2 in a manner analogous to its
interactionwith the p85 subunit. Additionally, there is ambigu-
ity regarding the identity of the kinase that activates PLC2,
with both Syk and Btk having been implicated (17, 32).
To address these questions, pulldown assays using BCAPL
and human PLC2 (PLC2-V5) were carried out in the pres-
ence or absence of either human YFP-tagged Syk or GFP-
tagged Lyn. The results presented in Fig. 5A show that FLAG-
BCAPL associates with PLC2-V5 in the presence and absence
of either YFP-Syk orGFP-Lyn.Moreover, the addition of Syk or
Lyn did not increase the apparent binding of BCAPL to PLC2,
suggesting that the interaction between BCAP and PLC2 may
be promoted by endogenous tyrosine kinases in these experi-
ments. However, it is apparent from the presence of a higher
molecular mass band of BCAP that it is phosphorylated by the
transfected Lyn kinase. BCAP was also able to pull down both
Lyn and Syk in the absence and presence of PLC2 (Fig. 5A).
Consequently, BCAP is phosphorylated by Lyn and forms a
complex containing either Syk or Lyn kinases and PLC2 irre-
spective of its activation by kinase.
We also investigated the ability of PLC2 to interact with the
TIR domain-containing proteins SARM, MAL/TIRAP, and
MyD88. Both MyD88 and MAL/TIRAP were able to interact
with PLC2. In contrast, SARM appears not to associate
directly with PLC2 ( Fig. 5B).
Discussion
Information flow through the TLR pathway is initiated by
ligand binding to leucine-rich repeats on the receptor ectodo-
main followed by receptor dimerization. Subsequently, homo-
typic associations of cytoplasmic receptor TIR domains and
those of various adaptor molecules including MyD88, TRIF,
MAL/TIRAP, TRAM, and SARM ensue, setting in motion a
cascade of molecular interactions that result in many cellular
responses including the production of pro-inflammatory mol-
ecules (33). Until recently, the known cytoplasmic TIR-con-
taining adaptorswere thought to be involved in direct stimulus-
driven TLR signaling only. However, the observation that an
adaptor molecule, BCAP, which is involved in BCR signaling, a
pathway seemingly unrelated to TLRs, was a negative regulator
of inflammation prompted a search for “missing” TIR domains
in the human genome and the postulate that BCAP possesses a
hidden N-terminal TIR domain (14).
Herewe showconclusively that BCAPhas anN-terminal TIR
domain that structurally bears closest resemblance to the ho-
mologous domain in TLR2. The isolated TIR domain of BCAP
FIGURE 3. AUC analysis of BCAP splice variant and N-terminal variant. A and B, sedimentation velocity profiles, residuals, and sedimentation coefficient
distribution, c(S), for the splice variant BCAPS, which lacks the first 180 amino acids and contains the DBB domain and ANK repeats (residues 322–403) (A), and
BCAP330, which consists of the N-terminal 330 residues and includes the putative TIR and DBB domains (B). Both are dimeric, revealing that the DBB and ANK
domains are responsible for BCAPL self-association. Every third scan is shown for clarity.
TIR Domain of the BCAP Adaptor
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is monomeric both in the crystal and in solution, a feature
shared with most non-plant TIR domains (34), suggesting that
vertebrate TIR domain-containing proteins require other
domains to promote self-oligomerization: leucine-rich repeats
(LRRs) for the TLR, a death domain for MyD88, and the DBB
domain and likely the ANK repeats for BCAP. The BCAPL par-
alogue, BANK1, which regulates CpG-induced IL-6 production
(35), also has a TIR domain as the corresponding domains have
high sequence homology (40%).
A strong interaction with MAL/TIRAP, TLR4, and TLR2 is
also detected in yeast two-hybrid assays. This implies that the
dimeric BCAP TIR domain makes multiple interactions with
the TLR post-receptor complex. MAL/TIRAP is of particular
interest because this adaptor localizes to the plasmamembrane
by binding to PIP2, an association that is required for signaling
(36).
Together our findings provide evidence that BCAP is part of
a membrane-bound network that down-regulates inflamma-
tory signaling by the TLRs. Thus, activation of PI3K and PLC2
results in the conversion of PIP2 to PIP3 and inositol 1,4,5-
triphosphate (IP3), respectively, leading to depletion of MAL/
TIRAP from themembrane (Fig. 6B) and negative regulation of
MAL/TIRAP-dependent TLR signaling.
The association between BCAP and PLC2 appears to be
more stable than the transient interaction observed between
BANK1 and PLC2 (37) and may reflect cooperative effects in
complex assembly. In contrast, the association between human
MAL/TIRAP or MyD88 and PLC2 appears to be less stable
than that of BCAPwith PLC2, which likely reflects the central
role played by BCAP in modulating all three pathways. Our
finding that BCAP interacts directly with PLC2 is consistent
with published reports linking BCAP to PLC2-dependent cal-
cium release (16). Calcium release initiated by the cleavage of
PIP2 by PLC2 releases diacylglycerol and the potent second
messenger IP3, which subsequently interacts with IP3 recep-
tors in the endoplasmic reticulum (38). The resulting calcium
flux activates both TLR signaling (17, 39–41) and the traffick-
ing of TLR4 to endosomal compartments (17).
It is also likely that BCAP is the “missing link,” coupling LPS
activation of TLR4 to endocytosis and the TRAM/TRIF path-
way that induces interferon-. Zanoni et al. (42) have shown
that the extrinsic membrane pattern recognition receptor
(PRR) CD14 is required for the LPS-induced internalization of
the TLR4 post-receptor complex and that this function of
CD14 is dependent upon the activation of both Syk and PLC2.
A further correlation involves the potential role of MAL/
TIRAP as a promiscuous lipid-binding protein (43). Although
this sorting adaptor had only been implicated in signaling from
the cell surface TLR2 and TLR4, Bonham et al. (43) present
evidence that MAL/TIRAP is required for resident endosomal
TLRs such as TLR9, at least in response to natural viral infec-
tion rather than synthetic ligands such as phosphorothioate
CpG-containing oligonucleotides. Endosomal membranes lack
PIP2, but MAL/TIRAP may bind to other phospholipids that
are abundant in this compartment such as phosphatidylinositol
3-phosphate (PI(3)P). As noted, BCAPL also negatively regulates
FIGURE 4. Interaction of BCAP and other TIR domain-containing proteins. HEK 293T cells were overexpressed with Myc-TRAM, FLAG-BCAP, Myc-BCAP,
FLAG-SARM, Myc-MyD88, and a Myc-MyD88-FXXM mutant as indicated. Cells were lysed, and immunoprecipitation (IP) was performed using anti-FLAG
antibody. Precipitates were split and assayed for the presence of FLAG- or Myc-tagged proteins. A, BCAP shows no interaction with TRAM (lane 1, Myc-
TRAMFLAG-BCAP-FL; lane 2, Myc-TRAM). WCL, whole cell lysate. B and C, BCAP interacts with SARM (lane 1, Myc-BCAP-FL; lane 2, Myc-BCAP-FL and FLAG-
SARM) (B) andwith bothMyD88 and the FXXMmutant ofMyD88 (lane 1, Myc-MyD88-WT and FLAG-BCAP-FL; lane 2, Myc-MyD88-WT; lane 3, Myc-MyD88-FXXM
and Myc-BCAP-FL; lane 2, Myc-MyD88-FXXM) (C). HC and LC are the heavy and light chains of the mouse anti-FLAG antibody, respectively.
TIR Domain of the BCAP Adaptor
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endosomal TLRs, perhaps bymodulating the levels of these alter-
native phospholipids in endocytic vesicles. The precise pathways
that mediate this crosstalk remain to be elucidated.
There are other scenarios inwhichPLC2 activity is linked to
TLR pathway outcomes. PLC2 is crucial in the calcium signal-
ing response of TLR2 and TLR4 stimulation by their respective
ligands and is also required for the peptidoglycan-dependent
production of TNF and IL-6 (40). Additionally, the calcium
flux produced by PLC2 is crucial for TRIF-dependent activa-
tion of IRF-3 but not the LPS-induced activation of TNF (17).
The activation of PLC2 in BCR signaling in murine splenic
B-cells is the result of phosphorylation on Tyr-753, Tyr-759,
and Tyr-1217 by Btk, but in Ramos cells, phosphorylation of
Tyr-1217 is Btk-independent, implying the presence of Btk-de-
pendent and Btk-independent pathways (44). Indeed, its phos-
phorylation by Syk is implicated in the production of TNF
following stimulation of TLR9 by CpG. BCAP, however, is
involved in the production of IL-6 and IL-10 but not TNF
upon TLR stimulation (10). Thus, our finding that the associa-
tion of BCAP andPLC2 is not enhanced by co-expressionwith
Syk is consistent with those observations.
As summarized in Fig. 6, this study partially uncovers a com-
plex membrane-associated network that regulates inflamma-
tion by establishing a negative feedback loop betweenTLR acti-
vation and the metabolism of inositol phospholipids. Future
studies will elucidatemore fully the interactions in this network
and themolecular basis of themultitypic interactionsmediated
by the BCAP TIR domain.
Experimental Procedures
Protein Expression and Purification for Biophysical Analysis—
The N-terminal domain of human BCAP comprising residues
7–142 was cloned into pMCSG7 (DNASU) and expressed as an
N-terminal hexahistidine-tagged fusion protein in E. coli
FIGURE 5. BCAP associates with phospholipase C2 and the kinases Lyn and Syk. HEK 293T cells were overexpressed with PLC2-V5, FLAG-BCAP, Lyn-GFP,
YFP-Syk, and TIRAP-FLAG. Cells were lysed, and immunoprecipitationwas performedusing anti-FLAG antibody. Precipitateswere split and assayed for the presence
of V5-, FLAG-, GFP-, and YFP-tagged proteins as shown. A, the interaction between BCAP and PLC2 is independent of the tyrosine kinases Syk and Lyn; BCAP
associateswith Sykor Lynboth in thepresence and in the absenceof PLC2 (lane 1, PLC2-V5; lane 2, PLC2-V5 andFLAG-BCAP-FL; lane 3, PLC2-V5, FLAG-BCAP-FL,
andGFP-Lyn; lane 4, PLC2-V5, FLAG-BCAP-FL, and YFP-Syk; lane 5, FLAG-BCAP-FL andGFP-Lyn; lane 6, FLAG-BCAP-FL and YFP-Syk). B, bothMAL/TIRAP andMyD88
show reduced association with PLC2 relative to BCAP, whereas SARM does not interact with PLC2 (lane 1, PLC2-V5; lane 2, PLC2-V5 and FLAG-BCAP-FL; lane 3,
PLC2-V5andFLAG-SARM; lane4,PLC2-V5andTIRAP-FLAG; lane5,PLC2-V5andMyD88-FLAG).Theexpressionof-actinwasusedtoassesstherelativeexpression
levels of the transformed plasmids.HC and LC are the heavy and light chains of themouse anti-FLAG antibody, respectively.
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BL21DE3 cells (Novagen). After nickel-nitrilotriacetic acid
purification in 20 mM Tris, 20 mM NaCl, pH 7.5, samples were
treated with tobacco etch virus (TEV) protease to remove the
hexahistidine tag, and further purificationwas performed using
S200 (GE Healthcare) size exclusion chromatography in the
same buffer supplemented with 5 mM DTT. BCAPL (1–805),
BCAPS, and BCAP330 were cloned into the same vector with a
Strep-tag at the C terminus. Proteins were purified using a 5-ml
StrepTrap column (GE Healthcare), and proteins were eluted
using 2.5 mM desthiobiotin (Sigma) dissolved in the same buffer
with final purification on S200 size exclusion as described above.
Analytical Centrifugation and SEC-MALS—Sedimentation
velocitymeasurements were performed using a BeckmanXL-A
ultracentrifuge equipped with absorbance and interference
optical systems. Sample concentrations ranged from 0.3 to 1
mg/ml. Data were acquired every 300 s at rotor speeds of
30,000–40,000 rpmusing anAn60Ti rotor (BeckmanCoulter).
Buffer density and viscosity were estimated using SEDNTERP,
and the experimental data were analyzed using SEDFIT (45).
SEC-MALS data were obtained using an injection volume of 50
l and a Superdex 200 Increase 10/300 column (GE Health-
care). Multiangle light scattering and differential refractometry
data were acquired usingDAWN8 andOptilab T-rEX instru-
ments, respectively (Wyatt Technology), and data analysis was
performed using the ASTRA (v6.1) software package from the
manufacturer. Protein concentrations were 4, 2, and 0.8 mg/ml
for the TIR, BCAP330, and BCAPL, respectively.
Protein Production for Crystallization—Following nickel-ni-
trilotriacetic acid purification of the N-terminal domain of
BCAP, sampleswere treatedwith tobacco etch virus protease to
remove the hexahistidine tag and then buffer-exchanged using
a Hi-Prep 26/10 desalting column (GE Healthcare) into 50 mM
HEPES, 100 mM NaCl, 2 mM DTT, pH 7.5. Following lysine
dimethylation (46), samples were purified by size exclusion
chromatography into 20mMTRIS, 20mMNaCl, 5mMDTT, pH
7.5. Crystals were obtained using the sitting-drop vapor diffu-
sionmethod at 20 °C and protein concentrations of 5–7mg/ml.
The well solution contained 100 mM MES, pH 6.5, 2–10% PEG
400, 1.5–2.4 M (NH4)2SO4, and 1 mM 5-amino-2,4,6-triiodo-
isophthalic acid monohydrate (I3C) (18).
Crystallographic Data Collection and Structure Deter-
mination—Diffraction data were collected on the IO3 beam-
line (Diamond Light Source, Didcot, Oxfordshire, UK). Data
reduction and scalingwere performedusingXDS (47) andAim-
less (48). Initial phases using the anomalous signal from I3C
were obtained using SHELXD (49), and a partial model was
obtained using Buccaneer (50). Further rounds of manual
model building and refinement were performed using Coot
(51), O (52), and PHENIX (53), respectively.
Antibodies—The antibodies used were mouse -Myc (Santa
Cruz Biotechnology), mouse monoclonal -FLAGM2 (Sigma-
Aldrich), rabbit -FLAG (Sigma-Aldrich), and -V5-HRP con-
jugate (Invitrogen).
Yeast Two-hybrid Assays—The bait plasmid for yeast two-
hybrid assay was generated by inserting the first 434 amino
acids of human BCAP (Source Bioscience) in-frame into the
pGBKT7 vector (Clontech) to be expressed as a GAL4-DBD
fusion protein. The prey plasmids were generated by inserting
FIGURE 6. Negative regulation of TLR4 signaling by BCAP and PLC2. A, MD2/LPS binding to the TLR4 ectodomain enables the recruitment of a cytosolic
signalosome comprising the PIP2-linked adaptorMAL/TIRAP and theMyddosome (MyD88 and interleukin-1 receptor-associated kinase (IRAK) kinases), which
interactwith the receptor TIR domains. The flux, F, through this pathway stimulates the production of NFB. B, PLC2-linked BCAP cleaves PIP2 toDAGand IP3,
which deprives MAL/TIRAP of its membrane anchor. Additionally, PI3K further depletes PIP2 by converting it to PIP3. MAL/TIRAP is still capable of interacting
with PIP3, but it is inactive presumably because it can no longer recruit the Myddosome. The net result is a reduction in flux, (F  m), and thus negative
regulation, of the MD2/LPS-induced stimulation of TLR4. IP3 produced by PLC2 cleavage of PIP2 stimulates calcium release from the endoplasmic reticulum
(ER), which in turn drives the internalization of TLR4 into endosomal compartments, leading to the production of interferon regulatory factors (IRFs).
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either the full-length proteins or different protein mutations
and truncations in-frame into the pGADT7 vector (Clontech)
to be expressed as GAL4-AD fusion proteins. The TIR domain
of TLR2 contained residues 636–784, whereas the TIR domain
of TLR4 comprised residues 671–820. Protein-protein interac-
tions were assayed by transforming the bait plasmid into the
yeast strain AH109 (Clontech) and the prey plasmids into the
yeast strain Y187 (Clontech) using standard lithium acetate
transformation (54) with the Matchmaker yeast two-hybrid
system (Clontech). The Leu and Trp transformants were
selected on SD/Leu and SD/Trpplates, respectively. For the
interaction analysis, equally dense suspensions of each trans-
formant were prepared in 0.5 yeast extract, peptone, dextrose
and adenine broth, mixed, and allowed tomate for 21 h at 30 °C
with shaking at 50 rpm. The respective pair of transformants
(bait and prey) was then plated onto SD/Leu/Trp plates for
assessing mating efficiency and on SD/Leu/Trp/His/
AdeX-Gal 5 mM 3-amino-1,2,4-triazole (3-AT) plates
for assessing the interaction. Negative controls were the empty
vectors of pGBKT7 and pGADT7 treated similarly.
Pulldown Assays—Human BCAP and splice variant was
cloned into either p3XFLAG-CMV-10 or pCMV/Myc vectors.
Protein constructs were transfected into HEK 293T cells
(ATCC, Manassas, VA) (70–80% confluence) using JetPEI
(Polyplus-transfection SA) according to the manufacturer’s
recommendations. 3 g of plasmid DNA was transfected per
well in a 6-well plate. When required, pcDNA3.1 was included
to ensure that the total DNA transfected was 3 g. The trans-
fection mixture was incubated for 24 h, after which cells were
washed once in 1 PBS and lysed using 300 l of a solution
containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% Non-
idet P-40, pH 8.0, which was supplemented with 1% Triton
X-100, 0.5% n-octylglucoside, 1 mM PMSF, and 1 protease
inhibitor cocktail (Calbiochem). After incubation on ice for 10
min, the mixture was transferred to an Eppendorf tube, and
lysis was continued for an additional 30 min at 4 °C with
agitation, after which the mixture was centrifuged at
16,000  g for 10 min at 4 °C, and the supernatant was col-
lected for analysis by Western blotting or for immunopre-
cipitation with anti-FLAG M2 beads (EZview Red anti-
FLAGM2 affinity gel, Sigma). 250 l of the extracted protein
sample was incubated with anti-FLAG beads for 2 h at 4 °C
with constant rotation, after which non-specifically bound
proteins were removed by repeated centrifugation at 1000
g and resuspension of the beads with 500 l of lysis buffer.
After the final wash, excess solution was aspirated, and 30 l
of 1 SDS loading buffer was added to the beads and heated
at 100 °C for 10 min. Finally, the protein samples from whole
cell lysate and immunoprecipitation were analyzed byWest-
ern blotting using the indicated antibodies.
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SUPPLEMENTARY MATERIALS
Supplementary Table S1: Crystallographic Statistics for theN-terminal
TIR domain of human BCAP
BCAP-TIR (I3C)
Data Collection
Space group P62 2 2
Cell dimensions
𝑎 = 𝑏, 𝑐 (Å) 135.04, 42.91
Resolution (Å) 44.2–2.5
Total reflections 99543 (9785)
Unique reflections 15066 (1489)
𝐼/𝜎𝐼 24.8(7.2)
Completeness (%) 99(98)
Redundancy 6.6(6.6)
Wilson B-factor 53.84
R-merge 0.047 (0.24)
R-meas 0.051 (0.26)
CC1/2 0.99 (0.98)
CC* 1.0 (1.0)
Phaser-EP FOM 0.35
Refinement
No. reflections 15066 (1489)
𝑅𝑤𝑜𝑟𝑘/𝑅𝑓 𝑟𝑒𝑒 0.19/0.24
No. atoms
Protein 1088
Ligands 32
Avg. 𝐵-factor 59.7
R.m.s. deviations
Bond lengths (Å) 0.012
Bond angles (Degrees) 1.60
Validation
Ramachandran favoured/allowed (%) 96/100
Rotamer Outliers (%) 7.8
Clashscore 7.7
                      .                                             . 
           10         20        30         40        50          60   
BCAP                    S                                                  I I  A Q LQ FL I T R S DL...........GCD L VY PD. EEWC Y TL SSRQV.RSQK L H LGPE..ASF AE SLF.L
MAL                     S                                                  V V  D Q LV LE S L Q A SS.....SSRWSKDYD C CH EE. LVAA D SY GSTTPGGAIV E C ......... L. .....
TLR1                    S                                                  A I  S N LL LE I L E V NINIPLEELQRNLQFH F SY GHD FWVK E PN KEG.....MQ C H RNFVPGKSI E. ITCIE
TLR2                    S                                                  A V  A N MV LE L L K I NI..........ICYD F SY ERD YWVE L QE NFNP...PFK C H RDFIPGKWI D. IDSIE
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                ..         . . .. ..                         
      70          80            90                 100        110     
BCAP                                                       L               T VV LLS LVQ Q RV R LS RC V AE H..FHKPSLLPL.L. ..R..AF...HPP.....H V CGVRD.SEEFLD..
MAL                                                        L               S RV LIT FLQ L TI L S. HC L PG DPWCK....YQMLQA ..T..EE...GC....... P .GL.SRAAYP.P..
TLR1                                                       L               S SI VLS FVQ E LI I LK YK F PN S..EW....CH..Y. L.Y..FAHHNLFHEG.SNS L .EP.IPQYSI.PSS
TLR2                                                       L               S TV VLS FVK E AI I LK HK F EN S..EW....SK..Y. LDF..SH..FRLF.....A L .EP.IEKKAI.PQR
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TLR10         E    YL                ANLRAAI                                YHKLKALL .KKA  EWP...KDRRKCGLFW       N........
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Supplementary Fig. S1: Structural alignment of the BCAP-TIR and the TIR-domains of MAL
(2y92), TLR1 (1fyv), TLR2 (1o77), TLR6 (4om7) and TLR10 (2j67). The secondary structural
elements shown are those of the BCAP-TIR domain (5for).
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Supplementary Fig. S2: Size exclusion chromatography in combination with multi-angle light
scattering (SEC-MALS) and differential refractometry data for the N-terminal TIR domain of
BCAP (A), BCAP330 (B) and BCAPL (C). Plots show the normalised UV (280 nm) light scat-
tering, refractive index and weight-averaged molecular mass (MW) variation across the peak in
addition to the MW at the peak. The molecular weights obtained by SEC-MALS are in complete
agreement with those obtained by sedimentation velocity.)
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Supplementary Fig. S3: The highly conserved proline residue (P49) in the 𝛽B-loop of BCAP
is not required for Mal/TIRAP interaction. HEK293T cells were transfected with FLAG-Mal,
Myc-Mal and Myc-BCAP as described. Both 𝛽B loop proline mutations (P49A/P49D) allowed
the BCAP-Mal/TIRAP interaction (lanes 4–5) to occur. Mutations in the 𝛼C′ helix (L75A) and
outside the TIR domain (L401A) both exhibit reduced interaction with Mal/TIRAP (lanes 2–3)
while the D117A (lane 1) mutation which lies in the region connecting the 𝛼D helix and 𝛽D
strand completely abolishes the BCAP and Mal/TIRAP interaction.
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B
Supplementary Fig. S4: Interaction of BCAP-TDA and various TIR domain containing pro-
teins determined by Yeast two-hybrid. Panels (A) and (C) were used to access transformation and
mating efficiency on SD/-Trp/-Leu media. BCAP-TDA interacts with wild-type MAL/TIRAP
and its mutants D96N and S180L (3, 5 and 7)(B) and with the TIR domains of TLR2 and TLR4
(D) (11 and 13) respectively on SD/-Trp/-Leu/-His/-Ade/+X-𝛼-Gal+5mM 3-AT. The full matrix
of the prey and bait plasmids used are shown below.
pGADT7 pGADT7[TIRAP] pGADT7[D96N] pGADT7[S180L]
pGBKT7[BCAP-TDA] 1 3 5 7
pGBKT7 2 4 6 8
pGADT7 pGADT7[TLR2] pGADT7[TLR4] pGADT7[TIRAP]
pGBKT7[BCAP-TDA] 9 11 13 15
pGBKT7 10 12 14 16
Supplementary Table S2: Plasmids and primers used for protein expression in bacteria, yeast and human cells.
The restriction sites used, when relevant are shown.
Protein Oligonucleotide Sequence (5′ → 3′) Vector
BCAP-TIR(F) TACTTCCAATCCAATGCCCCCAGAGGATGCGACATCCTCATC pMCSG7
BCAP-TIR(R) TTATCCACTTCCAATGTTAGGAAATGGCTTTTTTCACAGCTGCCAC
BCAP𝑆(F) TACTTCCAATCCAATGCCATGGTGGTGCAGCCGGACCG pMCSG7
BCAPL/S(R) TTATCCACTTCCAATGTTACTTCTCGAACTGGGGGTGACTC pMCSG7
CAGCGTCCTCTGGGTGG
BCAPL/330(F) TACTTCCAATCCAATGCCATGGCAGCCTCAGGG pMCSG7
BCAP330(R) TTATCCACTTCCAATGTTACTTTTCAAACTGCGGATGCGACCAG
GCACTGGCATTTGTCATCATATCTTCTTCTTCCAGCTGGTTG
FLAG-BCAPL(F) ATCAAGCTTATGGCAGCCTCAGGGGTGCC (HindIII) pCMV10
FLAG-BCAPL(R) ATCGGATCCTCAGCGTCCTCTGGGTGGAACAGG (BamHI)
Myc-BCAPL (F) Same as FLAG-BCAPL(F) (HindIII) pCMV-Myc
Myc-BCAPL (R) ATCGGTACCGCGTCCTCTGGGTGGAACAGG (KpnI)
Myc-BCAP-SV (F) ATCAAGCTTATGGTGGTGCAGCCGGACCG (HindIII) pCMV-Myc
Myc-BCAP-SV (R) ATCGGTACCGCGTCCTCTGGGTGGAACAGG (KpnI)
BCAP-TDA (F) ATCCATATGATGGCAGCCTCAGGGGTGCC (NdeI) pGBKT7 AD
BCAP-TDA (R) ATCGGATCCTCACGAGCATTTCATAAGCAGGTCTGTGG (BamHI)
MAL (F) ATCCATATGATGGCATCATCGACCTCCCTCCC (NdeI) pGBKT7 AD
MAL (R) ATCGGATCCTCAAAGTAGATCAGATACTGTAGCTGAATCCCG (BamHI)
TLR2-TIR (F) ATCCATATGAGCAGGAACATCTGCTATGATGCATTTGTTTC (NdeI) pGBKT7 AD
TLR2-TIR (R) ATCGGATCCTCAGGACTTTATCGCAGCTCTCAGATTTACC (BamHI)
TLR4-TIR (F) ATCCATATGGAAAACATCTATGATGCCTTTGTTATCTACTCAAG (NdeI) pGBKT7 AD
TLR4-TIR (R) TCGGATCCTCATGATTTACCATCCAGCAGGGCTTTTCTG (BamHI)
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